0008 International Publication WO 99/16442 and U.S. Pat. No. 6, 197 ,339 B1 describe a maleate salt of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ijquinolin 2(1H)-one, a compound of formula (I). In addition, a crystal Structure of the maleate Salt of a compound of formula (I) is described in an article by Heier et al. (Heier, R. F., Dolak, L.
A., Duncan, J. N., Hyslop, D. K., Lipton, M. F., Martin, I. Feb. 24, 2005 J., Mauragis, M.A., Piercey, M. F., Nichols, N. F., Schreur, P. J., Smith, M. W., Moon, M. W. (1997) Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H imidazo 4,5,1-jquinolin-5-amine and its metabolites. J. Med. Chem. 40; [639] [640] [641] [642] [643] [644] [645] [646] . These references, however, do not disclose a Salt of a compound of formula (I) and an artificial Sweetener or a crystalline Salt of a compound of formula (I) and an artificial Sweetener, nor do they disclose a therapeutically effective dose of less than 8 mg/day. In addition, these references do not disclose the compound (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij quinoline-2(1H)-thione or salts thereof. 0009 International Publication WO 02/062315 describes a compound of formula (I), and in preferred embodiments, compounds of formula (II) CH N N X 0010 where X is O or S. Although some embodiments described in this reference include formulations comprising a mixture of a compound of formula (II) and a Sweetener, the Sweetener is preferably Selected from Sucrose, mannitol, propylene glycol, Sodium Saccharin, aceSulfame K, neotame, and aspartame. A Salt of a compound of formula (I) and an artificial Sweetener is not disclosed, nor is a crystal line Salt of a compound of formula (I) and an artificial Sweetener disclosed, including a Salt or crystalline Salt of a compound of formula (I) and Saccharinic acid or cyclamic acid.
BRIEF DESCRIPTION OF THE INVENTION
0011. In accordance with the present invention, the inventors herein have Succeeded in discovering Salts com prising artificial Sweeteners and tricyclic compounds of formula (I). In preferred embodiments, the Salts are Substan tially crystalline in form. The Salts can be used in rapid release formulations that are particularly useful for treatment of Sexual dysfunction. 0012. Thus, in one embodiment, the invention comprises a pharmaceutical composition comprising a Salt, the Salt comprising an artificial Sweetener and a compound of for mula (I) US 2005/0043296 A1 0013 where 0014) R, R and R are the same or different and are: -H, C-C alkyl, C-C alkenyl, C-C alkynyl, C-C cycloalkyl, C-Co cycloalkyl, phenyl Substi tuted C-C alkyl, -NRR where R and R are cyclized with the attached nitrogen atom to produce pyrrolidiyl, piperidinyl, morphoninyl, 4-methyl pip erazinyl or imidazolyl, 0015 X is: -H, C-C alkyl, -F, -Cl, -Br, -I, -OH, C-C alkoxy, cyano, carboxamide, carboxyl, (C-C alkoxy)carbonyl, 0016 A is: CH, CH, CH-(halogen) (where halogen is C1, F, Br, or I), CHCH, C=O, C=S, C-SCH, C=NH, C -NH, C-NHCH, C-NCHCOOCH, C-NHCN, SO, N; 0.017) B is: CH, CH, CH-(halogen) where halogen is as defined above, C=O, N, NH, N-CH, 0.018 D is: CH, CH, CH-(halogen) where halogen is as defined above, C=O, O, N, NH, N-CH; and n is 0 or 1, and where 0019) 0020 (1) that when n is 0, and 0021 A is CH, CH-(halogen) where halogen is as defined above, CHCH, C=O, C=S, C=NH, SO; then 0022 D is CH, CH-(halogen) where halogen is as defined above, C=O, O, NH, N-CH; 0023 (2) that when n is 0, and 0024) A is CH, C-SCH, C-NH, C-NHCH, C-NHCOOH, C-NHCN, N; then D is CH, N; 0.025 (3) that when n is 1, and 0026 A is CH, CH-(halogen) where halogen is as defined above, CHCH, C=O, C-S, C=NH, SO; and 0027 B is CH, CH-(halogen) where halogen is as defined above, C=O, NH, N-CH; then 0028 D is CH, C=O, O, NH, N-CH; 0029 (4) that when n is 1, and 0030) A is CH, C-SCH, C-NH, C-NHCH, C-NHCOOCH, C-NHCN, N; and 0031) B is CH, N; then 0032) D is CH, C=O, O, NH, N-CH: 0033 (5) that when n is 1, and 0034) A is CH, CHCH, C=O, C=S, C=NH, SO, and 0035 B is CH, N; then 0036) D is CH, N.
is a single or double bond, with the provisos: Feb. 24, 2005 0037. In certain embodiments, the composition is a salt comprising an artificial Sweetener and a compound of for mula (I). In preferred embodiments, the compound is (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij-quino line-2(1H)-thione. The artificial Sweetener is any artificial Sweetener that can be combined with the compound to form a Salt, and is preferably Selected from the group consisting of Saccharinic acid and cyclamic acid. 0038. In another embodiment, the composition comprises a crystalline Salt, the crystalline Salt comprising an acid of an artificial Sweetener and a compound of formula (I). Prefer ably, the compound is (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij-quinoline-2(1H)-thione. The acid of the artificial Sweetener of the crystalline Salt is preferably cyc lamic acid.
0039. In another embodiment, the composition comprises a Salt, the Salt comprising an artificial Sweetener and a compound of formula (I), wherein the composition has a Sexually therapeutic effective amount as well as a Sexually useful effective amount of from about 0.2 to about 8 mg/perSon/dose. In another embodiment, a composition of the present invention rapidly disintegrates when placed in an oral environment. The composition thereby provides a fast melt medicament that is palatable or organoleptically acceptable to a recipient. 0040. In one embodiment, the composition is in a dosage form comprising the crystalline Salt and a pharmaceutically acceptable excipient. The dosage form is administered orally. The dosage form disintegrates rapidly upon intraoral administration, while having acceptable organoleptic prop erties. The dosage form preferably disintegrates in the mouth without the need for drinking water or other liquid, and provides a therapeutic, interest-enhancing or performance enhancing effect within about 10 minutes to about 8 hours after administration. 0041. Also provided by the present invention are methods of preparing the Salts described herein. In addition, the present invention provides methods of preparing crystalline salt forms. The latter methods involve dissolving a com pound of formula (I) and an acid of an artificial Sweetener in an organic Solvent to form a Solution, and precipitating a crystalline salt form from the solution. The artificial Sweet ener is, preferably, cyclamic acid, and the organic Solvent is, preferably, a mixture of tetrahydrofuran and methanol. In additional embodiments, dosage forms of the invention are provided that comprise a Salt or a crystalline Salt of the invention combined with one or more pharmaceutically acceptable excipients, as well as methods of preparing these dosage forms. 0042. Also provided by the present invention are methods of use of compositions of the present invention for treatment of Sexual dysfunction and for enhancement of Sexual desire, interest or performance. In this embodiment, a therapeuti cally effective amount of a Salt, preferably a crystalline Salt, of a dosage form of the invention is placed in the oral cavity. Interactions of the dosage form with fluids in the oral cavity lead to rapid disintegration of the dosage form, leading to rapid absorption and consequent therapeutic or Stimulatory effect.
0043. Further areas of applicability of the present inven tion will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and examples, while indicating pre ferred embodiments of the invention, are intended for pur poses of illustration only and are not intended to limit the Scope of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS 0044 FIG. 1 presents differential scanning calorimetry traces for the maleic acid (labeled as "maleate") and cycla mic acid (labeled as "cyclamate") crystalline salts of (R)-5, 6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij-quinoline 2(1H)-thione. 004. 5 FIG. 2 presents powder X-ray diffraction patterns of the maleic acid (labeled as "maleate") and cyclamic acid (labeled as "cyclamate') crystalline salts of (R)-5,6-dihydro 5-(methylamino)-4H-imidazo4.5-ij-quinoline-2(1H)-thione.
DETAILED DESCRIPTION OF THE INVENTION
0046) The present invention provides a composition which comprises a Salt, the Salt comprising a compound of formula (I) and a water soluble acid which is an artificial Sweetener. A salt of the invention is of high water solubility and has an acceptable taste, thus providing a rapid onset pharmaceutical composition useful for treatment of Sexual dysfunction, Stimulation of Sexual activity and enhancement of sexual desire, interest, and performance in men and Women. The compositions dissolve rapidly when placed in the environment of the oral cavity, thereby providing a fast-melt medicament which is rapidly absorbed. 0047 A composition of the present invention is effective in treating Sexual dysfunction at a dose of less than about 8 mg and, in particular, about 0.2 to about 8 mg/perSon/dose, preferably, about 0.5 to about 5 mg/perSon/dose, more preferably, about 1 to about 3 mg/perSon/dose. AS used herein, dosage amounts refer to the amount of the pharma ceutical compound rather than the amount of a Salt or a composition comprising the compound. For example, a dosage of "8 mg means a dosage of 8 mg of the compound, rather than 8 mg of a Salt comprising an acid and the compound. 0.048. The artificial Sweetener acid which provides the anion of the Salt comprising formula (I) masks the taste of the compound of formula (I), thereby obviating the need to administer compounds of formula (I) in a tablet or capsule to avoid the unpleasant taste of the compound. A further benefit of the invention is that the low dosage required for a pharmaceutical effect reduces undesired side effects of the medication. Yet another benefit of the invention is that rapid dissolution of a dosage form provides rapid onset of action following administration, for example rapid dissolution of a dosage form following placement in the oral cavity. amounts. However, in Some embodiments, the molar ratio of the artificial Sweetener to that of the compound is more or less than 1:1, So that a free base form of the compound coexists with the Salt, to adjust the taste of the dosage form. 0053. In another preferred embodiment, the invention comprises a crystalline Salt, the Salt comprising an artificial
Sweetener and a compound of formula (I). Preferably, the crystalline salt is the cyclamic acid salt of (R)-5,6-dihydro
0054. In preferred embodiments, the amount of the salt is lower than an amount causing Significant Side-effects. In the present invention, dosage amounts of the compounds of formula (I) lower than 10 mg do not lead to significant side-effects. Preferably, a dosage form of the salt of a compound of formula (I) is lower than 10 mg, more pref erably about 8 mg or less. 0055. The compounds of the present invention are pref erably in a pharmaceutical composition containing unit doses. By unit dose or unit dosage form, it is meant that the active compound is present in a discrete, known amount in the pharmaceutical composition. Such unit doses are effec tive in treating conditions of Sexual disturbance or in improving Sexual performance. The pharmaceutical compo Sitions of the present invention, in unit dosage form, com prise an amount of from about 0.05 mg to about 8 mg of the compound of formula (I), preferably about 0.1 to about 3 mg of the compound of formula (I), and more preferably about 0.25 mg to about 1 mg of the compound of formula (I). 0056 The precise dosage of a compound of formula (I) which is useful in the treatment of Sexual disturbances or to improve or increase Sexual interest or performance will depend upon the route of administration, the particular compound used, the particular condition being treated, the Severity of the condition being treated, the age, weight, general physical condition of the particular patient and the like as can be readily determined by the skilled artisan. 0057 The present invention includes, in some embodi ments, dosage forms for peroral administration, for example tablets and capsules. Any methods that are known in the art can be used to prepare these dosage forms. Such dosage forms can comprise, in addition to a Salt or a crystalline Salt of the present invention, one or more components that are known in the art. Table 1 presents analytical results for crystals of the cyclamate salt of (R)-5,6-dihydro-5-(methylamino)-4H imidazo4.5-ij-quinoline-2(1H)-thione described in Example 1. Because the material obtained from the Saccha rinate Salt was non-crystalline, no comparable Studies were conducted. 0.138. As various changes could be made in the above methods and compositions without departing from the Scope of the invention, it is intended that all matter contained in the above description be interpreted as illustrative and not in a limiting Sense. 0139 All references cited in this specification are hereby incorporated by reference in their entirety. The discussion of the references herein is intended merely to Summarize the assertions made by their authors and no admission is made that any reference constitutes prior art relevant to patent ability. Applicant reserves the right to challenge the accuracy and pertinency of the cited references.
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What is claimed is:
1. A pharmaceutical composition in unit dosage form comprising a Salt, the Salt comprising an acid of an artificial Sweetener and a compound of formula (I): (1) that when n is 0, and A is CH, CH-(halogen) where halogen is as defined 10. A pharmaceutical composition according to claim 9, which is in a unit dosage form comprising a dosage form comprising from about 0.05 mg to about 8 mg of the compound.
11. A pharmaceutical composition according to claim 10, which is in a unit dosage form comprising from about 0.1 mg to about 3 mg of the compound.
12. A pharmaceutical composition according to claim 11, which is in a unit dosage form comprising from about 0.25 mg to about 1 mg of the compound.
13. A method for treating Sexual dysfunction in a Subject, the method comprising orally administering to the Subject a pharmaceutical composition in a unit dosage form compris ing a Salt, the Salt comprising an acid of an artificial
Sweetener and a compound of formula (I): (1) that when n is 0, and A is CH, CH-(halogen) where halogen is as defined above, CHCH, C=O, C=S, C=NH, SO; then D is CH, CH-(halogen) where halogen is as defined above, C=O, O, NH, N-CH; (2) that when n is 0, and A is CH, C-SCH, C-NH, C-NHCH, C-NH COOH, C-NHCN, N; then D is CH, N;
(3) that when n is 1, and A is CH, CH-(halogen) where halogen is as defined (1) that when n is 0, and A is CH, CH-(halogen) where halogen is as defined above, CHCH, C=O, C=S, C=NH, SO; then D is CH, CH-(halogen) where halogen is as defined 
